



(PBPK) Linked to Pharmacodynamics: 
In silico and in vitro Parameterization





• PBPK background and principles
– Pioneers who have influenced our thinking
– Why PBPK compared to compartmental?
– Perfusion limited vs. Permeability limited
– Equations for transport and clearance
• In silico generation of organ physiology 
(PEAR)





Pioneers who influenced our thinking
• Teorell (1937) 
• Rowland: Nestorov, Blakey (iv barbiturates), 
Kawai (iv, po cyclosporin), Rodgers (iv, po β-
blockers) 
• Stanski: Wada (iv thiopental) 
• Krishnan: Poulin (in silico Kps), Haddad (in 
silico organ physiology) 
• Price (in silico organ physiology)
• Brown (in vivo organ physiology)
• Sugiyama, Holford, Houston
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Why PBPK?
• Physically relevant model
• Amenable to inter-species scaling
• Simulate Cp vs. time from in vitro data




































• Perfusion Limited Tissue:
– Well Mixed
– Rapid membrane permeation
– Same unbound concentration in interstitial and 
intracellular space
– Preferential partitioning to tissue (Kp)
Vv, Cv, fup






• Permeability Limited Tissue
– Slow permeation across cell membranes
– Unbound concentrations in intracellular and 
interstitial space are different

















Automatically generates all 
tissue parameters for selected 
ethnic group, gender, and age.




National Health and Nutrition 
Examination Survey (NHANES) 2001 –
2002 data
• 11,039 people participated
– 5331 males, 5708 females
– 3293 Hispanic
– 4606 Non-Hispanic White
– 2681 Non-Hispanic Black
– 459 other race
• Collected Weight, Height, BMI, 







In Silico Tissue Distribution
• Predicting Tissue/Plasma Partition (Kp):
– Poulin & Thiel
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GastroPlus Generates PBPK 
Parameters for You




































































































X[D] – fraction of neutral drug species in intracellular water (IW, pH=7) and plasma (P, pH=7.4)
K – vegetable oil/water partition coefficient for adipose tissue and 1-octanol/water partition coefficient for remaining tissues
fup-fraction unbound of drug in plasma, Ka – association constant of base with acidic phospholipids, [AP]T – tissue concentration of 
acidic phospholipids
RAt – tissue/plasma lipoprotein or albumin ratio
fupKpuKp *=
Unbound tissue plasma partition coefficient, Kpu, is calculated differently for strong 
bases than for other drugs.
1. Strong bases and zwitterions with at least one base pKa > 7 – takes into 
consideration the unique interaction of bases with acidic phospolipids (details)
2. Acids, Neutrals, and weak bases – takes into account binding to lipoproteins 























Drug and Excipient Interactions with all of the above.
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+ Apical Carrier-mediated Transport Rate
- Basolateral Transfer Rate
- Gut Metabolism Rate
Apical Carrier-mediated Transport rate = 
DFinflux(i) Vmax,influx C(i) / (Km,influx + C(i)) 
- DFefflux (i) Vmax,efflux Cu,ent(i) / (Km,efflux + Cu,ent(i))
DF = distribution factor for transporter amounts relative to 
Vmax measurement environment (when Vmax in a 
compartment is the same as Vmax in the measurement 











Lower Vmax Higher Vmax
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• Gut wall metabolism can be 
significant, especially for 
CYP3A4 and CYP2D6 
substrates
• Hepatic first pass is a function 
of the unbound concentration 
presented to the liver and 
hepatic blood flow rate
• Changing absorption location 
and rate can change both gut 









Calculation of hepatic 
clearance
Houston et al. (1997)
Step 1. In vitro incubation of drug with 
microsomes/hepatocytes/liver slices to obtain 
enzyme kinetic constants Vmax and Km and 
the in vitro intrinsic clearance 
Step 2. Scale in vitro enzyme kinetic 
constants to in vivo conditions based on 
species-specific physiological scale factors.
CLint in vitro
CLint (whole organ) in 
vitro
CLh (whole organ) in 
vivo
Step 3. Based on a hepatic blood flow model 
(e.g. Venous equilibrium model (1)), 
determine in vivo hepatic clearance. Rate of 
drug elimination = CLh × Concentration
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Significance of Gut Metabolism 
and Controlled Release
GPEN, Kansas, 2006
Gut Metabolism Scale Factors
Paine MF and Thummel KE, JPET, 1997; 283(3): p. 1552-
62.
Liver CYP3A = 5489 nmol
Liver Wt. = 1800 g
MicProt = 52.5 mg / g liver
CYP3A4 = 69.7 pmol / mgP
3A4 (nmol)   =  9.7        38.4      22.4
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Image J Analysis of
Jejunum vs. Colon Metabolism Scale 
Factors
Liver CYP3A = 5489 nmol
Jejunum CYP3A4 = 38.4 nmol
Colon CYP3A4 = 0.6 - 6.7 nmol
McKinnon, Gut 36(2):259 (1995)
Jejun……………………Colon……………………..
6799                 226     409 1171 419    855 110
One Jejunum and 10 colon samples. Samples without
Integration numbers were below baseline.
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Intestinal and Hepatic CYP 3A4 



































Vmax = 850 pmol/min/mg
Km = 4 μM
Vmax/Km = 212
IR Intest. Extract. = 43%
Alprazolam
Vmax = 2680 pmol/min/mg
Km = 660 μM
Vmax/Km = 4.1
IR Intest. Extract. ~ 1%
Saquinavir
Vmax = 3960 pmol/min/mg
Km = 0.4 μM
Vmax/Km = 9900




Intestinal and Hepatic CYP 3A4 Metabolism
MWt = 325.8
Log P = 3.37 (Exp.)
pKa =6.15 Base (ADMET 
Predictor)
Solubility = 8.7 μg/mL @ pH 
7.7 (ADMET Predictor)
Peff = 12 x 10-4 cm/s
Dose = 7.5 to 30 mg
CYP 3A4 Km = 4 μM
Vmax = 850 pmol/min/mg prot.
VmaxPed = 561 pmol/min/mg
Midazolam





After grapefruit juice (gut 




















Kupferschmidt HH, Clin. Pharmacol. Therap. 58(1):20 (1995)
Agoram & Bolger, Adv. Drug Deliv. Rev. 50(1):S41 (2001)
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Non-linear Dose Dependence of 
Midazolam Metabolism in Gut and Liver
GastroPlus simulations of 
non-linear dose dependence 
for Midazolam.
(Agoram & Bolger, 2001)
Experimental GastroPlus Compartmental Simulated
Dose Cmax AUC Cmax AUC Fa% FDP% Fb%
7.5 0.028 69 0.021 65 99 45 24
15 0.056 154 0.052 158 99 55 29

















Midazolam (New dose design)
• Aim: To design a new 
formulation of MDZ to 
minimize first pass
• Method: Avoid gut 
metabolism by releasing 
drug in colon
• 0% released at 3h; 100% 
released at 5h
• Fb increases from 25% to 
45%
















Changes in CYP 3A4 Expression in 
Duodenum of Pediatric Subjects (1 – 12 yo)
Johnson, T.N., Br. J. Clin. Pharm. 51(5):451 (2001)
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GastroPlus with PBPK module:
Pediatric (5 yo) Stochastic population virtual trial:
Vmax(gut) = 100%, Km = 50%, SITT = 20%, ColonTT = 20%
Peff = 40%, Other Phys. Params = 10%
Johnson, T.N., Br. J. Anesth. 89(3):428 (2002)
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Oxybutynin IR vs CR Integral 
Tablet
Sathyan G, Br. J. Clin. Pharm. 52:409 (2001)






















Stom.     Jejunum     Ileoc.     AscCol.  DecCol.        Caco-2



















• Substrate for L-type amino acid transporter 
(LAT1)
– Similar distribution to PepT1 (high in duodenum)
• Log P = -1.36 (QP)     log D7.0 = -2.95 (Exp.)
• Acid pKa = 4.19 and Basic pKa = 10.14 (QP)
• LAT1 IC50 = 340 μM (58.2 μg/mL)
• Solubility~7.0 = 11.9 mg/mL (QP)   30 mg/mL 
(Exp.)
















Non-linear Dose Dependence for 
Gabapentin Absorption
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What if we could slowly release 
Gabapentin with a Gastric Retentive 








Simulation of Slow Gastric Release
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Monocarboxylate Transporter (MCT-1) 
Expression in Gut
Gill RK, Am. J. Physiol. :Cell Physiol. 289(4):846 (2005)
Jejunum     Ileum       Prox.      Distal Colon
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Gabapentin                           XP13512 (Xenoport)
Monkey Oral                         Monkey Intracolonic
Cundy KC, JPET 311 (1):324 (2004)
Dose = IR 36 mg-Eq GP / Kg
Dose = IC 10 mg-Eq GP / Kg
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Conclusions
• In silico estimates of biopharmaceutical 
properties are useful in early discovery.
• The combination of in silico, in vitro, and 
PBPK provide useful simulations prior to 
in vivo testing.
• Significance / Relevance of transporters 
can be studied with simulation.
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The End
